Business Overview and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of estimated useful lives of property, plant, and equipment

The estimated useful lives of property, plant, and equipment are as follows:


Building and improvements						10–50 years
Laboratory and other equipment						3–10 years
Furniture and fixtures						5 years

Property, plant, and equipment, net consists of the following:


	As of December 31,
(In millions)	2023		2022
Building and improvements	$	2,423.1	$	2,270.0
Leasehold improvements	133.9		114.3
Laboratory equipment	1,384.5		1,315.3
Computer equipment and software	389.7		337.4
Furniture, office equipment, and other	165.9		150.2
Land	283.1		264.5
Construction in progress	1,345.0		980.5
	6,125.2		5,432.2
Accumulated depreciation and amortization	(1,978.8)		(1,669.2)
	$	4,146.4	$	3,763.0

Summary of presentation in statement of operations of payments to and from collaborators

In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments. In general, the presentation of such amounts is summarized below.


Nature/Type of Payment						Statement of Operations Presentation
Regeneron's share of profits or losses in connection with commercialization of products						Collaboration revenue
Reimbursement for manufacturing of commercial supplies						Collaboration revenue
Royalties and/or sales-based milestones earned						Collaboration revenue
Reimbursement of Regeneron's research and development expenses						Reduction to Research and development expenses
Regeneron's obligation for its share of collaborator's research and development expenses						Research and development expense
Up-front/opt-in and development milestone payments to collaborators						Acquired in-process research and development expense
Reimbursement of Regeneron's commercialization-related expenses						Reduction to Selling, general, and administrative expense
Regeneron's obligation for its share of collaborator's commercialization-related expenses						Selling, general, and administrative expense
Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal						Cost of goods sold
Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)						Other operating income